Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.43 |
| ▸ | RELA | Q04206 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19001553 | 0.88 | TRPV1 (0.53) | TRPV1TSHRDEGS1PTGS1BRAF | |
| SCHEMBL18979433 | 0.72 | DEGS1 (0.53) | RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL31672286 | 0.72 | DEGS1 (0.53) | RAB9ANPC1KDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL18979442 | 0.72 | DEGS1 (0.63) | RAB9ANPC1TP53TSHRNFKB1 | |
| SCHEMBL18996621 | 0.72 | DEGS1 (0.63) | RAB9ANPC1KDM4ESMN1; SMN2DEGS1 | |
| SCHEMBL18979440 | 0.70 | DEGS1 (0.49) | RAB9ANPC1TP53NFKB1NFKB2 | |
| SCHEMBL18979502 | 0.70 | DEGS1 (0.58) | RAB9ANPC1KDM4EDEGS1 | |
| SCHEMBL31672276 | 0.70 | DEGS1 (0.67) | RAB9ANPC1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL18979414 | 0.70 | DEGS1 (0.67) | RAB9ANPC1TSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL15853484 | 0.70 | ALDH1A1 (0.57) | RAB9ANPC1KDM4ETP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10016398-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170172984-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10016398-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | CCNA1, CCNE1, CCNB1 | RAB9A 143/4885NPC1 1272/4885POLB 615/4885 |
| US-20170172984-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | CCNA1, CCNE1, CCNB1 | RAB9A 143/4885NPC1 1272/4885POLB 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.